The stock has a 36-month beta value of 1.36. Opinions on the stock are mixed, with 8 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for MRSN is 86.30M, and at present, short sellers hold a 11.44% of that float. On November 22, 2024, the average trading volume of MRSN was 1.02M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRSN) stock’s latest price update
Mersana Therapeutics Inc (NASDAQ: MRSN)’s stock price has gone decline by -10.81 in comparison to its previous close of 2.22, however, the company has experienced a -21.43% decrease in its stock price over the last five trading days. seekingalpha.com reported 2024-11-13 that Mersana Therapeutics, Inc. (NASDAQ:MRSN ) Q3 2024 Earnings Conference Call November 13, 2024 8:00 AM ET Company Participants Jason Fredette – SVP, IR Martin Huber – President & CEO Mohan Bala – SVP, Chief Development Officer Brian DeSchuytner – CFO & COO Conference Call Participants Tara Bancroft – TD Cowen Yen-Der Li – Leerink Partners Charles Zhu – LifeSci Capital Ashiq Mubarack – Citi Yige Guo – Guggenheim Justin Zelin – BTIG Operator Good morning, and welcome to Mersana Therapeutics Third Quarter 2024 Conference Call. Currently all participants are in listen-only mode.
MRSN’s Market Performance
MRSN’s stock has fallen by -21.43% in the past week, with a monthly drop of -3.88% and a quarterly rise of 26.92%. The volatility ratio for the week is 13.73% while the volatility levels for the last 30 days are 10.79% for Mersana Therapeutics Inc. The simple moving average for the past 20 days is -8.57% for MRSN’s stock, with a -26.57% simple moving average for the past 200 days.
Analysts’ Opinion of MRSN
Many brokerage firms have already submitted their reports for MRSN stocks, with Citigroup repeating the rating for MRSN by listing it as a “Buy.” The predicted price for MRSN in the upcoming period, according to Citigroup is $5 based on the research report published on November 15, 2024 of the current year 2024.
JP Morgan, on the other hand, stated in their research note that they expect to see MRSN reach a price target of $5. The rating they have provided for MRSN stocks is “Neutral” according to the report published on March 19th, 2024.
Wedbush gave a rating of “Outperform” to MRSN, setting the target price at $7 in the report published on February 29th of the current year.
MRSN Trading at -4.40% from the 50-Day Moving Average
After a stumble in the market that brought MRSN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.47% of loss for the given period.
Volatility was left at 10.79%, however, over the last 30 days, the volatility rate increased by 13.73%, as shares sank -1.49% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.86% upper at present.
During the last 5 trading sessions, MRSN fell by -21.43%, which changed the moving average for the period of 200-days by -44.85% in comparison to the 20-day moving average, which settled at $2.17. In addition, Mersana Therapeutics Inc saw -14.66% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRSN starting from Bala Mohan, who sale 1,884 shares at the price of $1.90 back on Oct 28 ’24. After this action, Bala Mohan now owns 54,731 shares of Mersana Therapeutics Inc, valued at $3,580 using the latest closing price.
Bala, Mohan, the Officer of Mersana Therapeutics Inc, proposed sale 1,884 shares at $2.04 during a trade that took place back on Oct 28 ’24, which means that Bala, Mohan is holding shares at $3,843 based on the most recent closing price.
Stock Fundamentals for MRSN
Current profitability levels for the company are sitting at:
- -2.28 for the present operating margin
- 0.48 for the gross margin
The net margin for Mersana Therapeutics Inc stands at -2.14. The total capital return value is set at -0.78. Equity return is now at value -280.29, with -34.51 for asset returns.
Based on Mersana Therapeutics Inc (MRSN), the company’s capital structure generated 0.96 points at debt to capital in total, while cash flow to debt ratio is standing at -3.82. The debt to equity ratio resting at 24.27. The interest coverage ratio of the stock is -19.77.
Currently, EBITDA for the company is -166.08 million with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 5.66. The receivables turnover for the company is 34.84for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
To sum up, Mersana Therapeutics Inc (MRSN) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
